Ubs Group Ag Vor Biopharma Inc. Transaction History

Ubs Group Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.0 - $2.2 $27,182 - $59,800	-27,182 Reduced 70.82%	11,201 $11,000
Q1 2024 May 13, 2024	BUY	$1.8 - $2.85 $810 - $1,282	450 Added 1.19%	38,383 $90,000
Q4 2023 Feb 09, 2024	BUY	$1.66 - $2.63 $35,811 - $56,736	21,573 Added 131.86%	37,933 $85,000
Q3 2023 Nov 09, 2023	BUY	$2.1 - $3.35 $12,898 - $20,575	6,142 Added 60.11%	16,360 $34,000
Q2 2023 Aug 11, 2023	BUY	$3.09 - $5.33 $31,573 - $54,461	10,218 New	10,218 $31,000
Q4 2022 Feb 08, 2023	BUY	$3.77 - $7.43 $15,407 - $30,366	4,087 New	4,087 $27,000
Q2 2022 Aug 10, 2022	BUY	$3.89 - $6.44 $3,364 - $5,570	865 New	865 $4,000
Q1 2022 May 16, 2022	SELL	$6.04 - $12.23 $43,288 - $87,652	-7,167 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$11.32 - $18.02 $80,711 - $128,482	7,130 Added 19270.27%	7,167 $83,000
Q3 2021 Nov 15, 2021	SELL	$12.24 - $20.38 $62,191 - $103,550	-5,081 Reduced 99.28%	37 $1,000
Q2 2021 Aug 13, 2021	SELL	$18.65 - $38.78 $36,833 - $76,590	-1,975 Reduced 27.84%	5,118 $95,000
Q1 2021 May 12, 2021	BUY	$30.96 - $54.08 $219,599 - $383,589	7,093 New	7,093 $306,000

41.2M

9.3K

100

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $33.1M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.